{"id":53780,"date":"2026-01-12T21:30:25","date_gmt":"2026-01-12T13:30:25","guid":{"rendered":"https:\/\/flcube.com\/?p=53780"},"modified":"2026-01-12T21:32:19","modified_gmt":"2026-01-12T13:32:19","slug":"nona-biosciences-partners-with-link-cell-on-car-t-discovery-using-hcab-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53780","title":{"rendered":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform"},"content":{"rendered":"\n<p><strong>Nona Biosciences<\/strong>, a wholly\u2011owned subsidiary of <strong>HBM Holdings Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG: 2142<\/a>), announced a <strong>multi\u2011target antibody discovery collaboration<\/strong> with <strong>Link Cell Therapies<\/strong>, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary <strong>HCAb Harbour Mice platform<\/strong> and <strong>NonaCarFx screening platform<\/strong> to develop novel CAR\u2011T cell therapy candidates for <strong>solid tumors and hematological malignancies<\/strong>. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-overview\">Collaboration Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Nona Biosciences (HBM Holdings subsidiary)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Link Cell Therapies (US\u2011based CAR\u2011T developer)<\/td><\/tr><tr><td><strong>Technology Platforms<\/strong><\/td><td>HCAb Harbour Mice, NonaCarFx<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Multi\u2011target CAR\u2011T cell therapy discovery<\/td><\/tr><tr><td><strong>Applications<\/strong><\/td><td>Solid tumors and hematological malignancies<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Not disclosed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-hcab-harbour-mice-amp-nonacarfx\">Technology Profile: HCAb Harbour Mice &amp; NonaCarFx<\/h2>\n\n\n\n<p><strong>HCAb Harbour Mice Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Generates <strong>fully human heavy\u2011chain\u2011only antibodies (HCAbs)<\/strong> with <strong>significantly reduced immunogenicity<\/strong><\/li>\n\n\n\n<li>Provides <strong>greater flexibility for CAR functional design<\/strong> vs. conventional antibodies<\/li>\n<\/ul>\n\n\n\n<p><strong>NonaCarFx Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR\u2011function\u2011based HCAb library screening<\/strong> system<\/li>\n\n\n\n<li><strong>Accelerates discovery<\/strong> of differentiated CAR\u2011T candidates<\/li>\n\n\n\n<li><strong>Integrated workflow<\/strong> from antibody generation to CAR\u2011T validation<\/li>\n<\/ul>\n\n\n\n<p><strong>Combined Advantage<\/strong>: The platforms enable rapid identification of <strong>novel CAR\u2011T binders<\/strong> with <strong>optimized specificity and reduced off\u2011target toxicity<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For Nona Biosciences<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Monetization<\/strong>: Validates HCAb platform in <strong>cell therapy space<\/strong>, beyond traditional antibody applications<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: Partnership with <strong>US firm<\/strong> strengthens <strong>international collaboration track record<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Retains <strong>rights to platform improvements<\/strong> and potential <strong>downstream economics<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For Link Cell Therapies<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Access<\/strong>: Gains <strong>exclusive access<\/strong> to <strong>best\u2011in\u2011class HCAb technology<\/strong> for CAR\u2011T discovery<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong>: <strong>Reduced immunogenicity<\/strong> and <strong>enhanced design flexibility<\/strong> vs. scFv\u2011based CAR\u2011Ts<\/li>\n\n\n\n<li><strong>Speed to Clinic<\/strong>: <strong>12\u201118 month faster<\/strong> discovery timeline vs. traditional methods<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-car-t-for-solid-tumors\">Market Opportunity: CAR\u2011T for Solid Tumors<\/h2>\n\n\n\n<p><strong>Global CAR\u2011T Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size<\/strong>: <strong>$4.5\u202fbillion<\/strong> (2025), projected <strong>$15\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Hematology Dominance<\/strong>: <strong>90%<\/strong> of approved CAR\u2011Ts target blood cancers<\/li>\n\n\n\n<li><strong>Solid Tumor Gap<\/strong>: <strong>&lt;5%<\/strong> of pipeline in solid tumors due to <strong>targeting challenges<\/strong> and <strong>toxicity<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Nona\u2011Link Pipeline Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Market<\/strong>: <strong>\u00a580\u2011120\u202fbillion<\/strong> (US$11\u201117\u202fbillion) for <strong>solid tumor CAR\u2011Ts<\/strong> in China\/US<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage<\/strong>: <strong>First HCAb\u2011derived CAR\u2011T platform<\/strong> with <strong>multi\u2011target capability<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Platform<\/th><th>Focus<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Nona Bio + Link Cell<\/strong><\/td><td>HCAb Harbour Mice + NonaCarFx<\/td><td>Multi\u2011target CAR\u2011T<\/td><td>Discovery<\/td><td><strong>Reduced immunogenicity, flexible design<\/strong><\/td><\/tr><tr><td><strong>Allogene<\/strong><\/td><td>AlloCAR\u2011T\u2122<\/td><td>Off\u2011the\u2011shelf CAR\u2011T<\/td><td>Phase\u202fII<\/td><td>Allogeneic, not autologous<\/td><\/tr><tr><td><strong>Caribou<\/strong><\/td><td>CRISPR\u2011edited CAR\u2011T<\/td><td>Solid tumors<\/td><td>Phase\u202fI<\/td><td>Gene\u2011edited, not HCAb\u2011based<\/td><\/tr><tr><td><strong>Arcellx<\/strong><\/td><td>DAR\u2011T\u2122<\/td><td>Hematology<\/td><td>Phase\u202fII<\/td><td>Novel binder scaffold<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Moat<\/strong>: HCAb platform offers <strong>10\u201120 year IP protection<\/strong> through <strong>patented transgenic mice<\/strong> and <strong>screening methodologies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>Deal Value<\/strong>: While terms undisclosed, comparable AI\u2011enabled discovery partnerships command:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Access Fee<\/strong>: <strong>USD\u202f5\u201115\u202fmillion<\/strong><\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: Up to <strong>USD\u202f200\u2011400\u202fmillion<\/strong> (IND, Phase\u202fI, II, III, approval)<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Low\u2011mid single\u2011digit<\/strong> on net sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Pipeline Value<\/strong>: Each validated CAR\u2011T candidate could unlock <strong>$1\u20113\u202fbillion<\/strong> in therapeutic value across <strong>solid tumor indications<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration\u2019s discovery timeline, clinical development, and market potential. Actual results may differ materially due to clinical validation risks, competitive dynamics, and regulatory acceptance of novel CAR\u2011T platforms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53785,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[21,129,916,4546,128],"class_list":["post-53780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-car-t","tag-hbm-holdings","tag-hkg-2142","tag-link-cell-therapies","tag-nona-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody discovery collaboration with Link Cell Therapies, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary HCAb Harbour Mice platform and NonaCarFx screening platform to develop novel CAR\u2011T cell therapy candidates for solid tumors and hematological malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform\" \/>\n<meta property=\"og:description\" content=\"Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody discovery collaboration with Link Cell Therapies, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary HCAb Harbour Mice platform and NonaCarFx screening platform to develop novel CAR\u2011T cell therapy candidates for solid tumors and hematological malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53780\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T13:30:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T13:32:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform\",\"datePublished\":\"2026-01-12T13:30:25+00:00\",\"dateModified\":\"2026-01-12T13:32:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780\"},\"wordCount\":523,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1201-1.webp\",\"keywords\":[\"CAR-T\",\"HBM Holdings\",\"HKG: 2142\",\"Link Cell Therapies\",\"Nona Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53780#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53780\",\"name\":\"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1201-1.webp\",\"datePublished\":\"2026-01-12T13:30:25+00:00\",\"dateModified\":\"2026-01-12T13:32:19+00:00\",\"description\":\"Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody discovery collaboration with Link Cell Therapies, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary HCAb Harbour Mice platform and NonaCarFx screening platform to develop novel CAR\u2011T cell therapy candidates for solid tumors and hematological malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53780\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1201-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1201-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody discovery collaboration with Link Cell Therapies, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary HCAb Harbour Mice platform and NonaCarFx screening platform to develop novel CAR\u2011T cell therapy candidates for solid tumors and hematological malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53780","og_locale":"en_US","og_type":"article","og_title":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform","og_description":"Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody discovery collaboration with Link Cell Therapies, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary HCAb Harbour Mice platform and NonaCarFx screening platform to develop novel CAR\u2011T cell therapy candidates for solid tumors and hematological malignancies.","og_url":"https:\/\/flcube.com\/?p=53780","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T13:30:25+00:00","article_modified_time":"2026-01-12T13:32:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53780#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53780"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform","datePublished":"2026-01-12T13:30:25+00:00","dateModified":"2026-01-12T13:32:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53780"},"wordCount":523,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp","keywords":["CAR-T","HBM Holdings","HKG: 2142","Link Cell Therapies","Nona Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53780#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53780","url":"https:\/\/flcube.com\/?p=53780","name":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53780#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp","datePublished":"2026-01-12T13:30:25+00:00","dateModified":"2026-01-12T13:32:19+00:00","description":"Nona Biosciences, a wholly\u2011owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi\u2011target antibody discovery collaboration with Link Cell Therapies, a California\u2011based chimeric antigen receptor (CAR) T therapy developer. The partnership will leverage Nona Bio\u2019s proprietary HCAb Harbour Mice platform and NonaCarFx screening platform to develop novel CAR\u2011T cell therapy candidates for solid tumors and hematological malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53780"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53780#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp","width":1080,"height":608,"caption":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1201-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53780"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53780\/revisions"}],"predecessor-version":[{"id":53786,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53780\/revisions\/53786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53785"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}